Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Recent advances in our understanding of basic neuroenteric mechanisms and the role of effectors and transmitters in the brain-gut axis have provided opportunities to develop new therapeutic agents for irritable bowel syndrome (IBS). Furthermore, human pharmacodynamic studies utilizing transit, colonic or rectal sensitivity, and brain imaging have been useful in determining therapeutic efficacy (particularly for drugs that act on motor function). This review provides an overview of medications that have not yet been approved for treatment of patients with IBS, yet have shown promise in phase IIB trials. These include drugs that act on the serotonin receptor and transporter system, antidepressants, norepinephrine reuptake inhibitors, opioids, cholecystokinin antagonists, neurokinin-antagonists, chloride channel activators, guanylate cyclase C agonists, atypical benzodiazepines, probiotics and antibiotics. The changing landscape in the regulatory approval process has impacted the development of IBS drugs. Guidance documents from regulatory agencies in Europe and the United States have focused on patients’ reported outcomes and associated quality of life. After a decade of experience with different endpoints that have generated some data on psychometric validation and unprecedented information about responsiveness of the binary or global endpoints to drug therapy, it is necessary to pursue further validation studies before or during pivotal phase IIB or III trials. The hope of providing relief to patients should galvanize all parties to achieve these goals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Functional Gastroduodenal Disorders
Tack, J., Talley, N. J., Camilleri, M., Holtmann, G., Hu, P., Malagelada, J.-R., & Stanghellini, V. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.059 · Cited by 2,418
Self-citationFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Validation of the Brief Pain Inventory for chronic nonmalignant pain
Tan, G., Jensen, M. P., Thornby, J. I., & Shanti, B. F. (2004) · The Journal of Pain · doi:10.1016/j.jpain.2003.12.005 · Cited by 1,416
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Defecation frequency and timing, and stool form in the general population: a prospective study.
Heaton, K. W., Radvan, J., Cripps, H., Mountford, R. A., Braddon, F. E., & Hughes, A. O. (1992) · Gut · doi:10.1136/gut.33.6.818 · Cited by 733
Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614
Cited by
The brain-gut axis in abdominal pain syndromes.
Mayer, E. A., & Tillisch, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-012309-103958 · Cited by 511
Cannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Clinical trial:Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome
Ducrotté, P. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i30.4012 · Cited by 272
Irritable bowel syndrome: towards biomarker identification
Clarke, G., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.08.001 · Cited by 181
manabe, N., wong, B. S., camilleri, M., burton, D., mckinzie, S., & zinsmeister, A. R. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01442.x · Cited by 142
Self-citationLjótsson, B., Hesser, H., Andersson, E., Lackner, J. M., El Alaoui, S., Falk, L., Aspvall, K., Fransson, J., Hammarlund, K., Löfström, A., et al. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.01.007 · Cited by 141
Basnayake, C., Kamm, M. A., Stanley, A., Wilson-O'Brien, A., Burrell, K., Lees-Trinca, I., Khera, A., Kantidakis, J., Wong, O., Fox, K., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30215-6 · Cited by 128
Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design
Trentacosti, A. M., He, R., Burke, L. B., Griebel, D., & Kennedy, D. L. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.12 · Cited by 42
Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders
Sanger, G. J., Chang, L., Bountra, C., & Houghton, L. A. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10369922 · Cited by 17
“in detail in previous reviews [Camilleri and Chang, 2008; Mayer et al. 2008], but a brief”
BackgroundMethodResultInfluentialSelf-citationCamilleri, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.20 · Cited by 16
Self-citation
Metadata
- Authors
- Camilleri, M., & Chang, L.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 135
- Issue
- 6
- Pages
- 1877-1891
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2064433763
- Cited by
- 74
- References
- 38
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.